EGM has been a disappointment - there's no other way to frame it. Chances are we will see a retrace to pre-EGM-hype levels.
I see most of the material from the EGM as a negative, and two points in particular: capital raising needed, and trial delays due to the inability to patent natural products.
Add probable delays to this, and I'm surprised that we haven't seen a sizeable fall. The correction should come this week.
